{"id":8355,"date":"2020-12-06T08:47:00","date_gmt":"2020-12-06T08:47:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&p=8355"},"modified":"2024-05-02T10:09:53","modified_gmt":"2024-05-02T08:09:53","slug":"leukocytapheresis-for-rheumatoid-arthritis-cases-that-are-super-resistant-to-any-class-of-biological-drugs-and-tofacitinib","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/fr\/professional\/scientific-corner\/leukocytapheresis-for-rheumatoid-arthritis-cases-that-are-super-resistant-to-any-class-of-biological-drugs-and-tofacitinib\/","title":{"rendered":"Leukocytapheresis for rheumatoid arthritis cases that are super-resistant to any class of biological drugs and tofacitinib"},"content":{"rendered":"
\n

Shunsuke Mori<\/a> Transfusion and Apheresis Science<\/a> Volume 59, Issue 6<\/a>,\u00a0December 2020, 102920 doi: 10.1016\/j.transci.2020.102920<\/a><\/p>\n<\/div>\n\n

\n

Many biological disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) are currently available as treatment options for\u00a0rheumatoid arthritis<\/a>\u00a0(RA), but a subset of RA patients shows inadequate responses to any of these DMARDs. This phenomenon, which we call super-resistance, is becoming a serious concern. In this study, I present two cases of super-resistant RA in which patients failed to respond to treatment with bDMARDs of any class as well as to tsDMARD therapy with\u00a0tofacitinib<\/a>. In these cases,\u00a0leukocytapheresis<\/a>\u00a0(LCAP), a treatment that removes overabundant leukocytes from the body, rapidly induced low disease activity and made patients subsequently responsive to previously ineffective DMARDs. My experience with the present cases suggests that LCAP is worth considering as an alternative therapeutic option for the management of RA patients with super-resistance to DMARD therapies.<\/p>\n<\/div>\n\n

\n

https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1473050220302342<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Shunsuke Mori Transfusion and Apheresis Science Volume 59, Issue 6,\u00a0December 2020, 102920 doi: 10.1016\/j.transci.2020.102920 Many biological disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) are currently available as treatment options for\u00a0rheumatoid arthritis\u00a0(RA), but a subset of RA patients shows inadequate responses to any of these DMARDs. This phenomenon, which we call super-resistance, is becoming […]<\/p>\n","protected":false},"template":"","scientific_tags":[424,212,213,74,453,336,384,661,450],"class_list":["post-8355","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-gma","scientific_tags-immunosuppressant-resistant","scientific_tags-infliximab-resistant","scientific_tags-leukocytapheresis","scientific_tags-rheumatoid-arthritis","scientific_tags-rheumatology","scientific_tags-steroid-resistance","scientific_tags-super-resistant","scientific_tags-tofacitinib"],"acf":{"sc_authors":"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1473050220302342<\/a>"},"yoast_head":"\nLeukocytapheresis for rheumatoid arthritis cases that are super-resistant to any class of biological drugs and tofacitinib - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/leukocytapheresis-for-rheumatoid-arthritis-cases-that-are-super-resistant-to-any-class-of-biological-drugs-and-tofacitinib\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Leukocytapheresis for rheumatoid arthritis cases that are super-resistant to any class of biological drugs and tofacitinib - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Shunsuke Mori Transfusion and Apheresis Science Volume 59, Issue 6,\u00a0December 2020, 102920 doi: 10.1016\/j.transci.2020.102920 Many biological disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) are currently available as treatment options for\u00a0rheumatoid arthritis\u00a0(RA), but a subset of RA patients shows inadequate responses to any of these DMARDs. This phenomenon, which we call super-resistance, is becoming […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/leukocytapheresis-for-rheumatoid-arthritis-cases-that-are-super-resistant-to-any-class-of-biological-drugs-and-tofacitinib\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-02T08:09:53+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/leukocytapheresis-for-rheumatoid-arthritis-cases-that-are-super-resistant-to-any-class-of-biological-drugs-and-tofacitinib\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/leukocytapheresis-for-rheumatoid-arthritis-cases-that-are-super-resistant-to-any-class-of-biological-drugs-and-tofacitinib\/\",\"name\":\"Leukocytapheresis for rheumatoid arthritis cases that are super-resistant to any class of biological drugs and tofacitinib - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2020-12-06T08:47:00+00:00\",\"dateModified\":\"2024-05-02T08:09:53+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/leukocytapheresis-for-rheumatoid-arthritis-cases-that-are-super-resistant-to-any-class-of-biological-drugs-and-tofacitinib\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Leukocytapheresis for rheumatoid arthritis cases that are super-resistant to any class of biological drugs and tofacitinib - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/leukocytapheresis-for-rheumatoid-arthritis-cases-that-are-super-resistant-to-any-class-of-biological-drugs-and-tofacitinib\/","og_locale":"fr_FR","og_type":"article","og_title":"Leukocytapheresis for rheumatoid arthritis cases that are super-resistant to any class of biological drugs and tofacitinib - Adacyte","og_description":"Shunsuke Mori Transfusion and Apheresis Science Volume 59, Issue 6,\u00a0December 2020, 102920 doi: 10.1016\/j.transci.2020.102920 Many biological disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) are currently available as treatment options for\u00a0rheumatoid arthritis\u00a0(RA), but a subset of RA patients shows inadequate responses to any of these DMARDs. This phenomenon, which we call super-resistance, is becoming […]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/leukocytapheresis-for-rheumatoid-arthritis-cases-that-are-super-resistant-to-any-class-of-biological-drugs-and-tofacitinib\/","og_site_name":"Adacyte","article_modified_time":"2024-05-02T08:09:53+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/leukocytapheresis-for-rheumatoid-arthritis-cases-that-are-super-resistant-to-any-class-of-biological-drugs-and-tofacitinib\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/leukocytapheresis-for-rheumatoid-arthritis-cases-that-are-super-resistant-to-any-class-of-biological-drugs-and-tofacitinib\/","name":"Leukocytapheresis for rheumatoid arthritis cases that are super-resistant to any class of biological drugs and tofacitinib - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2020-12-06T08:47:00+00:00","dateModified":"2024-05-02T08:09:53+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/leukocytapheresis-for-rheumatoid-arthritis-cases-that-are-super-resistant-to-any-class-of-biological-drugs-and-tofacitinib\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner\/8355","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/media?parent=8355"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific_tags?post=8355"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}